The safety profile of YUPELRI has been demonstrated in 3 clinical studies

  • Safety database included 2,285 patients with COPD in two 12-week efficacy studies and one 52-week long-term safety study1*
  • A total of 730 patients received YUPELRI 175 mcg once daily1

Adverse reactions from two 12-week placebo-controlled efficacy trials (N=813)

adverse events
Fewer patients discontinued treatment with YUPELRI (13%) than with placebo (19%)1

Safety results from a 52-week, long-term trial vs tiotropium (N=1,055)1

  • YUPELRI was studied in a 52-week open-label active control safety study in patients with COPD (YUPELRI 175 mcg QD, n=335; tiotropium 18 mcg QD, n=356)
  • The adverse reactions reported in the long-term safety trial were consistent with those observed in the 12-week placebo-controlled studies
*Included patients who received an investigational 88 mcg/day dose of YUPELRI.